To ask the Scottish Executive, with reference to paragraph 4.4 of Final Consensus Statement of the Royal College of Physicians' Consensus Conference on Hepatitis C, what its response is in respect of the call for new drug therapies. The regulation and safety of medicines is reserved and is the responsibility of the Medicines and Healthcare products Regulatory Agency (MRHA), or, for certain types of drugs, the European Medicines Agency (EMEA).The MRHA has advised that any new drug applications, including those for Hepatitis C must achieve the required standards of safety, quality and efficacy before being granted a licence.